ESMO 2022 | Therapeutic strategies to maximize sensitivity to endocrine therapy in breast cancer

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses strategies to enhance sensitivity to endocrine therapy in patients with breast cancer. Patients previously treated with CDK4/6 inhibitors tend to be less sensitive to endocrine therapies and targeted therapies such as everolimus and alpelisib are potential treatments for such patients. The Phase II MAINTAIN trial (NCT02632045) additionally highlights the potential of using alternative CDK4/6 inhibitors in patients who have progressed on CDK4/6 inhibitors. Dr Hamilton also comments on oral SERDS such as elacestrant, which was assessed in the Phase III EMERALD trial (NCT03778931), as well as amcenestrant. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.